Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma

Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shared the long-term findings from the pivotal CARTITUDE-1 trial, and highlighted future directions for CAR T-cell therapy in this disease.

Related Keywords

Massachusetts ,United States ,Dana Farber Cancer Institute ,Boston ,Nikhilc Munshi , ,Novartis ,Amgen ,Jerome Lipper Multiple Myeloma Center ,Harvard Medical School ,Correlative Science ,Kraft Family Chair ,Multiple Myeloma Immune Effector Cell Therapy ,Adaptive Biotechnologies ,Karyopharm Therapeutics ,